Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.rouse.com/magazine/news/rouse-ventures-team-scores-win-for-breast-cancer-detection-wearable-cyrcadia/
Rouse Ventures team scores win for breast cancer detection wearable Cyrcadia
Rouse Magazine Editor
18 Jun 2018
venturing
china
wearable technology
We are celebrating the successful closing of US$3.8 million in Pre-A round funding for our client Cyrcadia Asia, a Hong Kong-based company developing a wearable bra insert that detects breast cancer. The round was led by iFlytek, one of China’s leading artificial intelligence companies.
Cyrcadia’s device is a revolutionary sensor patch worn under a women’s bra which, with two hours of monthly wear, allows women to monitor their breast health from an app on their mobile phone. The technology uses cloud-based AI to monitor for circadian metabolic changes that are proven to correlate to the onset of cancer. The technology has particular advantages in Asia, where screening participation is low, cancer incidence rates are increasing, and the majority of the female population have dense breast tissue, for whom traditional imaging technologies are less accurate.
The deal marks a milestone for Rouse Ventures program, which was formed from a collaboration with boutique investment advisory firm Southern Capital Partners (“SCP”). The combined team is led by Rouse China veteran Chris Bailey and SCP CEO Mark Chennells, who between them have over 40 years’ experience on the ground in China. They were supported by Rouse consultant Nigel Wong, other Rouse analysts and Lusheng’s IP attorneys.
Cyrcadia has been Rouse Ventures program’s deepest engagement, with Cyrcadia Asia formed in 2017 by a consortium of investors led by Southern Capital Partners, under an exclusive license agreement negotiated with Cyrcadia Inc of the US. The closure of Pre-A funding enables Cyrcadia to complete product development and launch into Hong Kong in Q3 2018, with a Series A funding round planned for Q4 2018 to fund further expansion into ASEAN and China.
Rob Royea, CEO and Chairman of Cyrcadia Asia, said:
“The Rouse and SCP partnership has been absolutely crucial in building the company and attracting investment. Without the confidence in Rouse’s experience in IP deals in Asia, the company might never have taken the first step into this region. Our technology is perfectly suited to the Asian population, given the limitations of traditional screening modalities and the rapid rise in breast cancer incidence. We look forward to working with the Rouse network throughout Asia as we expand our presence.”
Luke Minford, CEO of Rouse, said:
“We are delighted to see Cyrcadia Asia close its seed funding, especially with a lead investor as exciting as iFlytek, and we look forward to supporting the next stage of the company’s growth. Rouse has always been an entrepreneurial firm that is dedicated to helping companies obtain real value from their intellectual property assets. Our Ventures program proves that we can go beyond traditional consulting services and be instrumental in bringing a ground-breaking and potentially life-saving technology to the world. We are fortunate to have found in SCP a partner with outstanding contacts and experience in capital raising who can work so seamlessly with us.”
I don't know this publication or if it's worth getting the full report but Cyrcadia is named amongst some big companies:
http://cherrygrrl.com/2018/07/01/global-healthcare-artificial-intelligence-market-2018-aicure-cyrcadia-health-google-ibm-microsoft-atomwise-lifegraph-modernizing-medicine/
Actually, they're not delinquent in their filing; they were right on time. However, even though the report is for the correct period, they typo'd the year on the date they filed. Unfortunate mistake you'd think they'd notice and correct but, being a little more hands-off on the operation side with Cyrcadia in charge of progress, Lifeline might not be paying as good attention to detail as they should. Your keen powers of observation should have allowed you to notice the discrepancy - or you did but would rather paint a bleak picture. Whatever floats your boat.
Okay... so, Train B left the station at 11am and was 60 miles behind. At 20 mph faster than Train A, it would make up 20 miles every hour. Therefore, it would take 3 hours from 11am to catch up(2pm) and slightly thereafter, Train B would overtake it.
Can you do the LLBO/Cyrcadia math for us again? I think I have the train question right, but I want to know when the LLBO ship will come in.
PS: Did you ever buy back in, Change, or stick solely with cryptos? I can't remember if you also sold Cyrcadia.
That would be one of my three guesses too. Due to the sentence structure and sentiments, PenBlanc, Stan the Ichimoku guy or, my strongest suspicion: my friend with the friend with a smelly foot!
Maybe we could add Roche to the potential exit-strategy buyers list if that is the goal.
One of the interesting names on the team is Director Claudia Suessmoth-Dyckerhoff. If you go to her China LinkedIn page, we can see not only that she's very experienced, accomplished and big company connected (to both Roche and Clariant), but she's also "location-appropriate" to the Asian markets.
Her LinkedIn introduction:
I am positively sticking with you!
Good, timely find! I check both websites every couple days, expecting news should be forthcoming in steady fashion soon. Right under the new addition of Marly Heidkamp release is a recent piece on restarting clinical trials. Although it's dated April 30, it wasn't on there more than two days ago. Thanks for the heads-up!
Time will tell, for sure. I've been in LLBO since 2004, so we know how to wait it out. The length of time produced the best climate for wearables and IOT but too much longer and the next best mousetrap is bound to be sprung. I was just really impressed by your spot-on valuation of Cytosorbents. Sepsis - a friend of my mom's ended up with it after a UTI of all things. I really think our iT-Bra wait is over. Looking forward to you saying "I told you so"!
Hey, Confirm. I looked at some of your past posts to see what other good nuggets you've had and CytoSorbents, although quite a while ago, looks like a great example of your price targets. I know it was back in 2011 but you nailed that one: $4.16-12.60 and it's now at $8.25. I hope you're as accurate with your LLBO estimates! (I don't really know anything about CytoSorbents or if you were able to wait that one out but it sounds like a familiar wait time, right?)
Understood and well put. Our perseverance and faith may very well not be monetarily rewarded but let's not close doors that don't need to be shut, especially with each other. :)
LOL. I remember there was another "blue" period for Change when disappointment and disillusionment of Lifeline's unkept promises made for some very bitter messages. No one could say anything positive or in defense of Lifeline without an earful of counter response. I looked back and it appears to be March and April of 2016. I thought Spring brought new hope and life!
But I understand the frustration. I just don't understand why now, if Change ended up selling - unless still invested in Cyrcadia and trying to prod them along. I think the problem with the message that started this was the insinuation that a 5-year trial on blood biomarkers would signal the end for iT-Bra technology. At least, that was the impression I got with the post. Then people tried to distinguish the difference and the frustration poured out again. No one likes the confidence in a decision to buy or sell stock being undermined but all of it is risky, especially here in the Pinks.
If five years isn't very long to wait for a trial, I don't think six more months to find out if Cyrcadia is truly making good on its promises is too long either - considering a lot of us have been waiting between 10 and 15 years. Like most of us have said, it's this year or "bust". And all technologies that are helpful for a common cause are welcome - it's not an us or them battle. We're all on the same team.
Sorry, Penblanc. Hopefully, your luck isn't like mine and the stock will skyrocket right after you sell your last share. But, in this case, good for us.
In bocca al lupo.
I agree. The amount of blood to test for a simple sugar can be done with a pin prick, but to test for the staggering number of cancers would be more in the "vial" range, I would think. As we saw from another poster, they have been having varying success with blood testing for different cancer types. However, breast cancer was one of the least successfully detected and at a fairly late stage. Once again, like mammograms for dense breast tissue and blood tests specifically for breast cancer, neither met the "early" detection goal. And a five-year study is not an eminent danger for the least invasive device with the most accuracy, which is the iT-Bra.
The iT-Bra is not meant to replace any other procedure or doctor's supervision, but to aid and supplement it where earlier detection is key. And, although the Asian market sales won't be a huge windfall to the bottom line of Cyrcadia Health U.S., it will be a great aid to manufacturing and marketing in the United States and other countries (hopefully) THIS year. We always have to be cautiously optimistic talking about years when previous estimates haven't materialized, but there are more concrete steps visible to have the hopefully optimistic sentiment.
Well, during these quiet days, I did come across something for Cyrcadia Asia that, at least, shows the name getting out there in Hong Kong:
http://www.hkahf.org.hk/event/women-of-hope-2018/
Just curious, Intexp - the annual report has been provided fairly consistently, since the "big thaw", on or before March 31st. This year, March 31st is a Saturday. Do you think LLBO will file it this Friday? And Cyrcadia Health has also released info along quarterly lines. Maybe some news before Easter weekend, right?
lol - you know what they say about people who die penniless... perfect timing. But we only need happy thoughts and a few legs up - chart legs, that is - not legs with toes pushing up daisies. No Russian roulette! We want to stick around for a trip to Disneyland or an Italian castle!
Whoa! If you think LLBO stock is risky, wait until you try Russian roulette! No need to lose your head over this. Let's call it a lottery play and hope for the best. We're all in this together.
They probably didn't want to mention it because the Mexican kid would get a hold of the newer design and claim he re-invented it again. Ha, ha. Kidding, friend. I think they clearly stated that they were waiting for the updated product to continue trials - but some trials have been completed and they already have the approval to sell under FDA Class II. I agree - that part was concerning to read about after the fact but we (or some of us) will wait and see (but wait less and see sooner). Have a good day, Friend(s).
Well, as you read in the Cyrcadia Health update, there will be more communication in the future, now that the dominoes - having been set - will start falling fairly quickly.
I guess it depends on your temperament.
Many of us who have been in this stock for over 10 years are "cautiously optimistic" with a tinge of excitement. Although it's been promised many times over that the product would be launched one year or the next, it definitely seems like things are falling in line for 2018. The recent rise in PPS is due both to a Lifeline update and a promising, detailed Cyrcadia Health update. There seems to be a genuine attempt to move the ball down the field now, and both websites - which have neglected to stay current on news and PRs - have become current; both are posting information pertaining to the progress and timeline and have stated that communication will be more forthcoming in the future. If you are an Amazon Prime member, you can watch the 15-minute Detected movie for free and get an idea of why there is some excitement. And that documentary was funded by Cisco. That name tends to get people excited. Also, go to either lbti.com or cyrcadiahealth.com websites and read through the latest update. It will lay out the plan for finally entering the market, first in Asia, followed by U.S.
I think the entry point for the publicly-traded stock of LLBO, which has a 40(ish) percent interest in privately-funded Cyrcadia Health, should be exciting if thinking about the near-term rise when solid, verifiable progress starts to be announced.
I did - but now I'm eagerly awaiting the sequel. I'm pretty sure Cisco didn't invest $1 million for just that 15 minutes, unless Melanie Griffith got a huge salary to narrate. It ends with a "to be continued" feel, so I hope they have plenty of new material to add to the future feature! :)
lol - good find. Can't we just be friends? Have a good day, Deep. I must away. Good luck to all.
I don't blame anyone invested for years to be somewhat skeptical when they hear repetitive news or conflicting information. However, to be locked into a negative spin seems like a reason to not waste anymore time on this stock - whether it's investing in it or posting messages constantly hammering away on anything positive.
For Deep, you could have simply gone to Cyrcadia's website and got the exact same information that was provided on Pitchbook (which was something posted quite a while back by another long - before, as was said, the CA deal) instead of wasting time digging on Google to prove your dilution point. The "Investors" tab states the stages they planned for private fund raising:
I think he was referring to Pen Blanc. Good to see you here!
lol - definitely! Waiting for him to copy and paste the pictures from the update that don't carry over here on IHub. I sense a newer "invention" will be posted on the Higia website - now a circular sensor on the front.
Great follow-up. We should have caught the clue from the Lifeline update that we were supposed to check Cyrcadia Health's "News" tab. The two large insurance entities, as referred, seem to be Dignity Health and Kaiser Permanente (huge in California). So, there's that. Here is the quoted Cyrcadia Health update in its entirety, for those who don't want to go to the website themselves:
Don't worry, Deep. You could, in fact, still be wrong. It said "at the time, the transaction was valued over 12 million", not "at the time, Lifeline was a 40% shareholder." Maybe the value is now worth more than 12 million... or less. There was supposedly still another fund-raising stage for Cyrcadia, which may result in dilution - or more cash that won't necessitate dilution. Perhaps the cash and stock purchase by Cyrcadia Asia caused them not to need more funds. But, that's the nature of relatively vague updates without solid progress and evidence to point to - it still makes it a guessing game with positive or negative potential. I think those who have some remaining hope are willing to stick it out another few months and wait for solid evidence of progress - but we won't be on the hook forever.
.25 by Friday, the ???? We forgot to be specific. Date, month and year?
What makes me like you is I laugh every time I see your name. My brother's friend spent a week on my couch once and I had to get rid of the couch. His friend's feet smelled too - and it wouldn't leave long after he was gone. Is your friend's name Steve? If only a teenager invented Febreeze 20 years ago. :)
This will probably be deleted "off topic" but I do wish you a smell-free evening. And don't dream about stinky investments. Life is good. Viva la LLBO!
Good thing this year is just beginning.
Buenas noches, Smelly Foot. Dulces sueños.
I understand the frustration. If it's not this year, I won't be holding my breath. At the rate of technological advancements, it pretty much is now or never, and there will always be a new teenager "inventing" more things that have existed - like songs of the 70s and a better mousetrap. Life's a gamble, so keep that sense of humor - it's critical.
What does it say when a teenage boy can claim to have invented something that existed before he was born? I don't see any proof of concept on their website. How do you know that it's been replicated? It is a pretty bra, pink for cancer awareness. I guess that's what sold you because there is no verifiable information on its accuracy and only vague statements on their plan. It's nice that a woman can use it in the "commodity" of her home - as long as she isn't jumping around in the sunlight when she runs the scan. Usually a problem.
You know what just happened? I invented a blood test to predict cancer before any current medical testing will find it. I'll get a website together and start selling it in a year or so.
But really - at what point did you slip your flip flops on and become an "everything is believable if it comes from anyone other than Cyrcadia" person? You used to be quite a defender in the beginning. I think the only way to settle it is to wait for the first bra in production. I raise my cup to you.
lol - yes, when you need cheaper drugs, medical procedures, think of Mexico - just don't expect laws and standards to protect you when they go bad.
I sure wonder what soured Smelly Foot here. Looking back on his/her first posts, they were very pro-Cyrcadia/LLBO. Now, he'd/she'd rather believe a Mexican teenager who "invented" the same device and protocol a year ago after it had been established by Lifeline for a decade. He'd rather believe cancerSEEK or whatever blood tests to improve their 33% success rate in a "year or so" and come to market. But if Cyrcadia says the same thing, don't believe it. If Cisco funds a documentary with $1 million, you'd be better off valuing the Mexican teen's $20,000 prize. If Stanford and Ohio State test the device and Flextronics produces it, be wary. Trust Mexico. Okay. Can you invest in EVA's private funding, Foot Smells? I would suggest you send your money there. It's practically a sure thing. The boy said so.
lol - Oh, wait. Another article.
But the article was your way of proving a point - and it's even less convincing hype. CancerSEEK is building on 30 years of research and not even near commercialization yet. But "they hope". Maybe all of it is scams and "cancer" is the bait. I guess this is the year LLBO/Cyrcadia will show or fold. If you invested in sub-penny pink sheet stocks, it's all pretty much a gamble, right?
Okay. I won't debate with you anymore. Have a good evening.
Mm-hmm. And I guess the same thing can be said for the projections in the "near future". We'll believe it when we see it. Their testing showed it was much better at late stage (III) cancer, and even then, was less accurate than the success rate of the iTbra. Maybe better for targeted therapy than detection.
Awesome article. Any advantage over cancer is a good thing. But did you even read the article supposedly proving your point? About halfway down:
"The test appeared to be more effective at finding some types of cancer than others, the authors noted. For example, it was able to spot ovarian cancer 98 percent of the time, but was successful at detecting breast cancer only 33 percent of the time."